AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study

Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for ​patients newly diagnosed with a type of ‌lymphoma reduced the risk of disease progression or death in...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。